mega swerte download The judge said he’ll make his decision after Combs’ lawyers and federal prosecutors file letters, due Monday, addressing outstanding issues.Saturday Night Live has lined up its last trio of hosts for 2024. After a season full of nostalgic bits, political bites, and even some emotional moments, Season 50’s first stretch will conclude with three back-to-back-to-back episodes in December. Here’s what to know about how to tune in for the last three episodes of the year.0 Yes! Saturday Night Live is new this weekend, on Saturday (December 7), with Gladiator II star Paul Mescal hosting and Shaboozey as musical guest. This marks Shaboozey’s first stint on SNL . After this week’s episode, two more consecutive shows have been announced. On December 14, Chris Rock will host for the fourth time, with Gracie Abrams as the musical guest of the week, making her SNL debut in support of her new album The Secret of Us . Then, on December 21, for the holiday episode, Martin Short will host for the third time, and Hozier will take the stage as musical guest, his second stint on the show in support of his new album Unreal Unearth . Saturday Night Live airs on Saturday evenings at 11:30 p.m. ET on NBC. Episodes are also available to stream Peacock , which boasts a sprawling library of all 49 seasons. SNL kicked off its 50th season early in October. Here’s a list of the episodes so far. The show will celebrate its 50th anniversary with an NBC special airing Sunday, February 16. Find out everything to know about that right here . More Headlines:

Kings vs. Pelicans Injury Report Today – December 12

So, King Charles III finally turned up for the Australian leg of his victory lap of the Commonwealth. History editor Dr Glenn Davies declares it's time an Australian head of state was one of us... and also a resident. IT'S BEEN OVER two years since then-Prince Charles stepped into the top job. A royal tour between 18 and 26 October 2024 marked the first time that Australians experienced a royal audience with their king. After over ten years, four governors-general and two monarchs, a sitting Australian Head of State finally appeared Down Under! Our absentee King’s 17,000-kilometre journey from the other side of the world saw Charles and his wife, Queen Camilla , grace us with the presence of a British Monarch on Australian soil for the first time as our Head of State (although the grace was presented only in Sydney and Canberra). King Charles III was greeted in Canberra by the Prime Minister, but not a single state leader — all declined their invitations , citing “other commitments” ranging from election campaigns to cabinet meetings. Paying a King's ransom King Charles-the-whatever is coming to Australia on 18 October until some other date you can no doubt find in your calendar, if you could be bothered. Queensland experienced its second King’s Birthday Public Holiday — even though KCIII’s actual birthday is 19 November. Queenslanders took the day off work; not in recognition of their hard work, but to recognise the British Monarch who will most likely be sleeping through our public holiday. The King’s Birthday Public Holiday doesn’t remind us of anything good about our country. At worst, it tells us Australia’s head of state gets the job by inheritance. Perhaps it would have been better if the British Monarch had turned up for "his" birthday weekend? I suppose, though, that would have been awkward: a public holiday in Queensland, only at this time of year (with WA a week before) and Queensland not even on the visiting schedule. Oops. The lack of actual public activity around King’s Birthday Public Holiday shows just how much the concept of monarchy is out-of-step with contemporary Australia. Since his birth as Prince Charles, KCIII has known he would one day take over the top job. One morning in 2022, Australians simply woke up to hear news from Britain that could affect our country for decades to come. Australians did not choose King Charles III as our Head of State. It is a disgraceful fact that without Constitutional change, the citizens of Australia will never be consulted on our head of state. Etiquette tips for awed commoners when meeting King Chukka Here are some vital deportment behavioural protocols in the face of British flapdoodle. It’s time for an Australian to be our head of state and do the job full-time rather than someone working from home at Windsor Castle — who can’t be bothered Zooming into an Australian office once a week. We are a unique multicultural country and we need someone who understands how to embody us, to be the guardian of our Constitution — to be a unifying symbol at home and someone we are proud to see representing us abroad. Our head of state should be elected on merit, not gifted this position by birthright. They should have the skills and work experience to do the job. It should be one of us. A person responsible and accountable to us and unwaveringly loyal to us — and only us. We have our own identity as Australians. The Royals represent Britain and cannot represent us or really unite us as Australians. So many Australians believe in freedom and equal opportunity — not that some are born to rule over others. We come from all walks of life, from all corners of the globe and this ancient land. Our shared commitment to our common future is what binds us together. Standing against this is the elevation of Charles III. I’ve argued previously here that there is no place for princes and kings in modern Australia. The public repudiation of former PM Tony Abbott’s knights and dames decision showed that Australia has moved on from the old colonial way of thinking. We can have respect and affection for Britain and its celebrity royals but still, question why we do not have our own head of state. The British Royal Family: A cult of obsession Support for an Australian Republic referendum is persistently stifled by the mainstream media's obsession with treating the Royal family as celebrities. The royals are welcome to visit as representatives of Britain, but I look forward to when the British people and their royal family will welcome a visit by the first Australian head of state. In the words of Australian comedian and radio presenter Sammy J : "So to our King, we say g’day and we praise his DNA, his ever-loyal subjects across the sea. We might have golden soil and a bit of wealth for toil, but us Aussies are still girt by monarchy." For us in Australia, royalty only ever visits us from somewhere else, from across the seas. It’s not something that lives with us. Royalty comes and royalty goes, but it is never a true part of us. Thanks Charles, but we’ve got it from here. Toodle pip. You can follow history editor Dr Glenn Davies on Twitter/X @DrGlennDavies . This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Australia License Support independent journalism Subscribe to IA. POLITICS REPUBLIC AUSTRALIA INTERNATIONAL KING CHARLES III Queen Camilla British Monarchy Royal Family #auspol head of state Republic Australian Constitution King’s Birthday Public Holiday Sammy J Share Article

' electrifying talent on the football field continues to be overshadowed by his questionable antics. The wide receiver has been during Week 13's matchup against the . These penalties-his fourth fine this season-highlight an ongoing battle between Pickens' undeniable potential and his struggles with discipline. In the game's first quarter, Pickens was . Later, in the third quarter, he celebrated a play with a , a move the NFL has aggressively cracked down on due to its violent connotations. This second infraction , bringing the total to over $20K for just one game. Steelers head coach didn't hold back in addressing the situation. " ," Tomlin told reporters after the game. Pickens' fine sparks questions about discipline This isn't the first time Pickens has been at the center of controversy. His history of fines includes , such as blindside blocks, excessive facemask penalties, and personal taunts. More recently, he was involved in a fight with defensive back and has faced accusations of taking plays off. Even off the field, Pickens drew attention for mimicking Marshawn Lynch's infamous " " moment during a post-Thanksgiving media exchange. Fans and analysts alike are divided on Pickens' behavior. While some admire his passion and fiery energy, -both in penalties and reputation. " " one observer mused. With 55 receptions for 850 yards and three touchdowns this season, Pickens' talent is undeniable. However, the narrative surrounding his career . As the Steelers push toward the playoffs, Pickens faces a pivotal moment: Will he refine his behavior and channel his energy productively, or will his actions continue to detract from his potential? The clock is ticking for the 23-year-old to grow into the player both fans and his team know he can be.

President-elect Donald Trump has tapped Brooke Rollins, president and CEO of the America First Policy Institute, to oversee the Department of Agriculture, one of the most sprawling federal agencies. Rollins was previously the director of the Domestic Policy Council during the first Trump administration. She has a long history in conservative politics, including also running the Texas Public Policy Foundation. Originally from Texas, she graduated from Texas A&M University with a degree in agricultural development. She then got her law degree at the University of Texas school of Law. During the first Trump administration, Rollins also served as assistant to the president for intergovernmental and technology initiatives . After leaving the White House, Rollins was among a group of senior advisers to create the new nonprofit group aimed at promoting Trump's policies . As the new head of USDA she would oversee nearly 100,000 employees, and would oversee the Supplemental Nutrition Assistance Program, which makes up over half of its nutrition budget, as well as the Supplemental Nutrition Program for Women, Infants, and Children (WIC) and school meal regulation. She would be the second woman to lead the department, following Ann Veneman who served under President George W. Bush. The department could be at the front lines of Trump's efforts to trim what he calls the "deep state" of federal bureaucracy and his efforts to implement tariffs on foreign goods — though it also provides crucial assistance to farmers and rural areas. The department distributes agricultural subsidies and is the first stop for farmers to receive financial assistance for their operations. USDA is also the only agency with a rural development branch that distributes federal broadband, housing and utilities programs to rural communities. The first Trump administration had to address the consequences of Trump's trade war with China and others, which resulted in retaliatory tariffs on U.S. agricultural products leading to decreased farmer profits . The federal government did step in with some assistance to boost incomes due to the trade war, and then the COVID-19 pandemic. It is possible Trump could also sign a second farm bill into law, a potentially trillion-dollar bill reauthorized every five years to provide farmer safety nets, programing, rural development and government nutrition assistance. The last farm bill was signed by Trump in 2018 and Congress has since failed to reauthorize it. SNAP is estimated to serve 42 million participants each month with food benefits, and WIC serves about 40% of all infants in the United States . Making changes to the safety-net programs has been one of the sticking points for the legislation, in addition to its funds for conservation programs. Copyright 2024 NPR

n a season marked by change and adaptation, the have seen stepping into a leadership role alongside , traditionally known as the team's "enforcer." While Brown has always been vocal about addressing issues directly, Barkley's influence has brought a new dimension to the team's dynamics. His ability to lead by example on and off the field and address challenges head-on has complemented Brown's approach. "What really brought us together was me being the enforcer on offense. I'd say the stuff nobody else wanted to. Then Saquon came in and took some of that pressure off me. He started speaking up too, and we just clicked," the wide receiver recently said. This has created a balanced leadership structure. This dual leadership has strengthened the team's cohesion and focus, allowing them to tackle obstacles collaboratively. Trouble in paradise Recent tensions have arisen between A.J. Brown and Jalen, with the wide receiver expressing frustration over the team's passing game. This led to speculation about a potential rift between the two. However, Hurts quickly clarified that there were no personal issues, stating, "We're good," and emphasized that Brown's comments were about the offense as a whole. Brown also reiterated that his remarks were not directed at Hurts but were aimed at improving the team's overall performance. As the Eagles push towards the playoffs, the combination of Brown's straightforwardness and Barkley's emerging leadership promises to be a significant advantage if things can be well with Jalen Hurts.Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE Amgen